Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female, 18 to 65 years of age, inclusive~* A current primary diagnosis of OAB~* Idiopathic detrusor overactivity, demonstrated by a urodynamic observation~* Evidence of frequency in combination with urinary urgency~* Written informed consent form~* Willingness to avoid pregnancy and practice adequate birth control~* Negative serum pregnancy test~* Agrees to refrain from blood donation during the course of the study~Exclusion Criteria:~* Subjects who are pregnant or lactating~* Clinically significant abnormality or clinically significant unstable medical condition~* QTc interval of 470 msec or greater at Visit 1~* Predominant stress urinary incontinence versus urge urinary incontinence based on subject history~* Neurogenic bladder (e.g. associated with spinal cord injury, multiple sclerosis, etc.)~* Anatomic or structural abnormalities possibly causing urinary incontinence or urgency, including but not limited to urogenital prolapse stage 2 or more according to the Pelvic Organ Prolapse Quantification (POP-Q) system~* Urological or gynecological surgery within 3 months of the baseline urodynamic assessment~* Current UTI or frequent UTIs (i.e., greater than or equal to 4 UTIs per year), interstitial cystitis, hematuria of unknown cause, or use of indwelling catheter~* Electro-stimulation therapy, bladder training, or physiotherapy for bladder control within 2 weeks of Visit 1~* History (within 1 year of Screening) of alcohol or substance dependence (except nicotine dependence) according to DSM-IV-TR criteria~* History of any kind of cancer within the last 2 years~* Existing non-malignant tumors that could compromise the function and/or anatomy of the lower urinary tract

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).